PE20231369A1 - Combinaciones para el tratamiento del cancer - Google Patents
Combinaciones para el tratamiento del cancerInfo
- Publication number
- PE20231369A1 PE20231369A1 PE2023000162A PE2023000162A PE20231369A1 PE 20231369 A1 PE20231369 A1 PE 20231369A1 PE 2023000162 A PE2023000162 A PE 2023000162A PE 2023000162 A PE2023000162 A PE 2023000162A PE 20231369 A1 PE20231369 A1 PE 20231369A1
- Authority
- PE
- Peru
- Prior art keywords
- combinations
- compound
- relates
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invencion se refiere a combinaciones que comprenden un inhibidor de punto de control y un inhibidor de c-Met, el Compuesto 1. La invencion tambien se refiere a formas cristalinas de la base libre del Compuesto 1, asi como tambien formas cristalinas de sales del Compuesto 1, en combinacion con un inhibidor de punto de control. La invencion tambien se refiere una composicion farmaceutica que comprende estas combinaciones. La invencion ademas se refiere a metodos para tratar un cancer administrando el Compuesto 1 como un agente unico o una combinacion descrita en este documento.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063059601P | 2020-07-31 | 2020-07-31 | |
US202063113556P | 2020-11-13 | 2020-11-13 | |
US202163148921P | 2021-02-12 | 2021-02-12 | |
PCT/US2021/043699 WO2022026706A1 (en) | 2020-07-31 | 2021-07-29 | Combinations for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20231369A1 true PE20231369A1 (es) | 2023-09-07 |
Family
ID=77431400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023000162A PE20231369A1 (es) | 2020-07-31 | 2021-07-29 | Combinaciones para el tratamiento del cancer |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230301979A1 (es) |
EP (1) | EP4188376A1 (es) |
JP (1) | JP2023536264A (es) |
KR (1) | KR20230059792A (es) |
CN (1) | CN116437954A (es) |
AU (1) | AU2021318134A1 (es) |
BR (1) | BR112023001792A2 (es) |
CA (1) | CA3186517A1 (es) |
CL (1) | CL2023000289A1 (es) |
CO (1) | CO2023001561A2 (es) |
CR (1) | CR20230052A (es) |
IL (1) | IL300151A (es) |
MX (1) | MX2023001298A (es) |
PE (1) | PE20231369A1 (es) |
TW (1) | TW202220654A (es) |
WO (1) | WO2022026706A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20230287A (es) * | 2018-01-26 | 2023-07-26 | Exelixis Inc | COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-358) |
WO2023172917A1 (en) * | 2022-03-07 | 2023-09-14 | Sanofi-Aventis U.S. Llc | Use of isatuximab in combination with other agents for the treatment of multiple myeloma |
WO2023196899A2 (en) * | 2022-04-08 | 2023-10-12 | Global Cancer Technology | Methods and products to screen and treat glioblastoma multiforme and other cancers, including breast cancers, using a combination of pi3kinase inhibitors with checkpoint inhibitors |
CN117285533B (zh) * | 2023-11-24 | 2024-01-30 | 四川省医学科学院·四川省人民医院 | CD47/SIRPα小分子抑制剂及其应用和抗肿瘤药物组合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014055897A2 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
EP2992017B1 (en) | 2013-05-02 | 2020-11-18 | AnaptysBio, Inc. | Antibodies directed against programmed death-1 (pd-1) |
CA3038500A1 (en) * | 2016-09-27 | 2018-04-05 | Andrea B. Apolo | Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
WO2018136796A1 (en) * | 2017-01-20 | 2018-07-26 | Exelixis, Inc. | Combinations of cabozantinib and atezolizumab to treat cancer |
CR20230287A (es) * | 2018-01-26 | 2023-07-26 | Exelixis Inc | COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-358) |
JP2022512399A (ja) | 2018-12-13 | 2022-02-03 | エグゼリクシス, インコーポレイテッド | キナーゼ阻害剤の結晶性形態及び塩形態 |
-
2021
- 2021-07-29 US US18/018,805 patent/US20230301979A1/en active Pending
- 2021-07-29 AU AU2021318134A patent/AU2021318134A1/en active Pending
- 2021-07-29 JP JP2023506226A patent/JP2023536264A/ja active Pending
- 2021-07-29 CA CA3186517A patent/CA3186517A1/en active Pending
- 2021-07-29 CR CR20230052A patent/CR20230052A/es unknown
- 2021-07-29 BR BR112023001792A patent/BR112023001792A2/pt unknown
- 2021-07-29 IL IL300151A patent/IL300151A/en unknown
- 2021-07-29 WO PCT/US2021/043699 patent/WO2022026706A1/en active Application Filing
- 2021-07-29 EP EP21758525.6A patent/EP4188376A1/en active Pending
- 2021-07-29 KR KR1020237006875A patent/KR20230059792A/ko unknown
- 2021-07-29 PE PE2023000162A patent/PE20231369A1/es unknown
- 2021-07-29 MX MX2023001298A patent/MX2023001298A/es unknown
- 2021-07-29 CN CN202180065378.8A patent/CN116437954A/zh active Pending
- 2021-07-30 TW TW110128221A patent/TW202220654A/zh unknown
-
2023
- 2023-01-30 CL CL2023000289A patent/CL2023000289A1/es unknown
- 2023-02-14 CO CONC2023/0001561A patent/CO2023001561A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2023000289A1 (es) | 2023-09-01 |
JP2023536264A (ja) | 2023-08-24 |
CN116437954A (zh) | 2023-07-14 |
MX2023001298A (es) | 2023-02-22 |
IL300151A (en) | 2023-03-01 |
US20230301979A1 (en) | 2023-09-28 |
AU2021318134A1 (en) | 2023-03-02 |
CA3186517A1 (en) | 2022-02-03 |
CR20230052A (es) | 2023-04-11 |
WO2022026706A1 (en) | 2022-02-03 |
KR20230059792A (ko) | 2023-05-03 |
EP4188376A1 (en) | 2023-06-07 |
BR112023001792A2 (pt) | 2023-04-11 |
TW202220654A (zh) | 2022-06-01 |
CO2023001561A2 (es) | 2023-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20231369A1 (es) | Combinaciones para el tratamiento del cancer | |
CL2021002965A1 (es) | Compuestos antivirales que contienen nitrilo. | |
ECSP21080535A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
CL2019001079A1 (es) | Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina. | |
CO2019005287A2 (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
CL2023000846A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
PE20191474A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer | |
CO2021015624A2 (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituída, composiciones de estos y métodos de tratamiento con dichos compuestos | |
CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
CL2020002544A1 (es) | Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret | |
CL2023002383A1 (es) | Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d | |
BR112015022820A8 (pt) | ensaio para selecionar um regime de tratamento para um indivíduo com depressão, uso de um composto compreendendo folato, composição e kit | |
CL2020002512A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak. | |
CO2022000481A2 (es) | Inhibidores de enzimas | |
CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
CL2021000030A1 (es) | Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales | |
CL2020003380A1 (es) | Compuestos que aumentan la actividad del proteosoma. | |
CO2021004004A2 (es) | Composición tópica inyectable | |
CO2022000266A2 (es) | Inhibidores de enzimas | |
CL2023000943A1 (es) | Formas cristalinas de un compuesto farmacéutico. | |
CL2023003045A1 (es) | Derivados de fósforo como nuevos inhibidores de sos1 | |
CL2022003812A1 (es) | Inhibidores de rip1k | |
BR112023021913A2 (pt) | Tratamento de câncer com inibidor de raf | |
BR112017014914A2 (pt) | terapia combinada para hipertensão pulmonar | |
ECSP23088732A (es) | Moduladores de trex1 |